Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2005
03/03/2005WO2005018650A2 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005WO2005018645A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018629A1 Treatment for acne vulgaris and method of use
03/03/2005WO2005018624A2 Methods of treating copd and pulmonary hypertension
03/03/2005WO2005018622A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
03/03/2005WO2005018621A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018619A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005WO2005018574A2 Immunostimulatory combinations and treatments
03/03/2005WO2005018540A2 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
03/03/2005WO2005018316A1 Hypertrophic cardiomyopathy model animal
03/03/2005WO2005000285A3 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
03/03/2005WO2004113274A3 Diaryl ureas with kinase inhibiting activity
03/03/2005WO2004110151A8 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
03/03/2005WO2004103274A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
03/03/2005WO2004094370A3 Antibacterial pyrazole carboxylic acid hydrazides
03/03/2005WO2004091476A3 Method of screening remedy for heart disease and medicinal composition for treating heart disease
03/03/2005WO2004089416A3 Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
03/03/2005WO2004073623A3 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
03/03/2005WO2004071383A3 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
03/03/2005WO2004035004A3 Effervescent compositions comprising bisphosphonates and methods related thereto
03/03/2005WO2004025256A3 Viral deconstruction through capsid assembly in vitro
03/03/2005WO2004012767A8 Medicinal agent and method for curing erectile dysfunction
03/03/2005WO2004012766A8 Method for correcting immune responses and medicinal agent
03/03/2005WO2004006936A8 Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005WO2003102151A3 Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
03/03/2005WO2003089418A8 Indane acetic acid derivatives and their use as pharmaceutical agents
03/03/2005WO2003048349A3 Acetoacetyl-coa thiolase and use of for the identification of novel fungicidal substances
03/03/2005WO2003045317A3 Therapeutic protein and treatments
03/03/2005WO2003042362A3 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
03/03/2005WO2002074911A3 Identification of gene expression alterations underlying the aging process in mammals
03/03/2005US20050049305 Preventing apoptosis of sensory hair cells in corti organ of fetuses during perinatal period by reducing ototoxic effects
03/03/2005US20050049299 Selective inhibitors of stat-3 activation and uses thereof
03/03/2005US20050049293 Increasing effect of released acetylcholine on hepatic muscarinic receptors
03/03/2005US20050049268 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
03/03/2005US20050049255 Synergistic combination of vasopressin receptor antagonist and phosphodiesterase inhibitor; dysmenorrhoea
03/03/2005US20050049243 Acetylcholinesterase (AChE), metabotropic glutamate receptor 2 (mGluR2); alzheimer's disease, cognitive impairment
03/03/2005US20050049233 Transdermal administering of testosterone
03/03/2005US20050049231 Local delivery of aromatase inhibitor using intravaginal device; estrogen dependent proliferative disorders of uterus; minimal side effects, longer term treatment, variable dosage
03/03/2005US20050049229 Antiinflammatory and/or antiplatelet aggregation actions; lower toxicity, reducing liver and/or kidney damage; analgesic and antipyretic activity
03/03/2005US20050049216 Immunostimulatory nucleic acid molecules
03/03/2005US20050049215 contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulating interferon-alpha to treat viral infections; oligonucleotide linked to a biodegradable delivery complex
03/03/2005US20050049212 Eating disorders, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea; drug screening; diagnosis and therapy; kits; regulates metabolism of triglycerides
03/03/2005US20050049205 Product from rose hips e.g. 3- beta -D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO); arthritis and osteoarthritis
03/03/2005US20050049190 Cation conducting gabaa receptors and their use
03/03/2005US20050048639 Caspase-8 binding protein, its preparation and use
03/03/2005US20050048584 Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof
03/03/2005US20050048528 Using immunoglobulins and diagnostic and/or prognostic tool for detection and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy
03/03/2005US20050048525 Amino acid sequences having hydrolase enzyme activity for use diagnosis, prevention and treatment of cardiovascular and gastrointestinal disorders; drug screening; bioassay
03/03/2005US20050048488 Expression vector comprising nucleotide sequences coding excitatory amino acid transporter 2 (EAAT2) proteins for use in identifying modulator for treatment and preention of neurological or psychiatric disorder
03/03/2005US20050048479 Adenylyl and guanylyl cyclases
03/03/2005US20050048148 Synergistic mixtures; balancing (pro/anti)inflammatory cytokines
03/03/2005US20050048130 Promotes respiration and results in no deleterious side effects
03/03/2005US20050048124 Antimicrobial composition for medical articles
03/03/2005US20050048119 Core containing antihypoglycemic agent with water soluble seal coating and semipermeable membrane
03/03/2005US20050048113 In situ administering of antisecretory agents and antacid
03/03/2005US20050048079 Induction response in cells; joining to adenosine triphosphate binding domain; therapy for Aids; anticancer agents
03/03/2005US20050048072 Topical administering mixtuure of immune response moderator and another drug
03/03/2005US20050048070 Mixture of polypeptides from cytokeratins; anticancer agnets; vaccines
03/03/2005US20050048068 Major histocompatibility complex epitopes; immunotherapy ; induce immunology response
03/03/2005US20050048062 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
03/03/2005US20050048055 Use of CD40 engagement to alter T cell receptor usage
03/03/2005US20050048044 Controlling, adjustment diffusion or degradation of membrane using activating energy source such as light source or ultraviolet radiation
03/03/2005US20050048035 Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
03/03/2005US20050048034 Using adipose stem cells to treat ischemic ulcer, diabetic and traumatic wounds; regenerative medicine
03/03/2005US20050048029 Nucleotide sequence for diagnosis, prevention, therapy of cancer, inflammation, autoimmune disease and infections
03/03/2005US20050047998 Phosphoprotein target for insulin and its antagonists
03/03/2005CA2848954A1 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
03/03/2005CA2551075A1 Immunostimulatory combinations and treatments
03/03/2005CA2536435A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005CA2536293A1 Methods of treating copd and pulmonary hypertension
03/03/2005CA2536288A1 Cancer metastasis inhibitor
03/03/2005CA2536280A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2536275A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005CA2536112A1 Methods for enhancing embryo viability
03/03/2005CA2536089A1 Ppar modulators
03/03/2005CA2535951A1 Bacterial strains, compositions including same and probiotic use thereof
03/03/2005CA2535814A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal
03/03/2005CA2535811A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2535803A1 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
03/03/2005CA2535745A1 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005CA2535585A1 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
03/03/2005CA2535583A1 Method of inducing immune tolerance
03/03/2005CA2535550A1 Treatment for acne vulgaris and method of use
03/03/2005CA2535063A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005CA2533126A1 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
03/03/2005CA2531022A1 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
03/02/2005EP1510521A1 Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
03/02/2005EP1510221A1 Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
03/02/2005EP1510219A1 Method for identifying at least one Aminopeptidase-inhibitor
03/02/2005EP1510216A1 Antithrombogenic platiniferous ceramic composition and article containing the same
03/02/2005EP1510206A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/02/2005EP1509772A2 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2)
03/02/2005EP1509768A2 Methods for cohort selection and longevity studies
03/02/2005EP1509621A1 Treatment with cytokines for alzheimer's disease
03/02/2005EP1509618A2 Autoimmune conditions and nadph oxidase defects
03/02/2005EP1509614A1 Map-kinase inhibitors as regulators of tumor-associated antigen expression
03/02/2005EP1509612A2 Transcellular drug delivery system
03/02/2005EP1509600A1 Plant thymidine kinases and their use
03/02/2005EP1509598A2 Induction of insulin expression
1 ... 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 ... 1151